Übersetzung für "Radiochemotherapie" in Englisch

The role of combined chemoradiotherapy in this setting is unclear.

Here, it is frequently in combined with chemotherapy as radio chemotherapy.

This actively personalized vaccine will be administered in addition to standard chemotherapy after surgery and initial radiochemotherapy are completed.

Usually, a non-operative therapy such as radio chemotherapy, chemotherapy, or radiation, or brachytherapy, are recommended.

During radiochemotherapy prophylactic administration of G-CSF is not recommended (D).

The safety of IMFINZI (10 mg/kg) has been evaluated in the PACIFIC Study (n = 475) in patients with locally advanced, unresectable NSCLC who had completed treatment with at least 2 cycles of concurrent chemoradiation within 1 to 42 days prior to initiation of the study.

Immune-mediated pneumonitis occurred more frequently in patients in the PACIFIC Study who had completed treatment with concurrent chemoradiation within 1 to 42 days prior to initiation of the study (10.7%), than in the other patients in the combined safety database (2.0%).

Three doses are given on three consecutive days before myeloablative therapy, finishing 24 to 48 hours before the therapy.

Where available, archival tumour tissue specimens taken prior to chemoradiation therapy were retrospectively tested for PD-L1 expression on tumour cells (TC) using the VENTANA PD-L1 (SP263) IHC assay.

The study excluded patients who had progressed following chemoradiation therapy, patients with prior exposure to any anti-PD-1 or anti-PD-L1 antibody, patients with active or prior documented autoimmune disease within 2 years of initiation of the study; a history of immunodeficiency; a history of severe immune-mediated adverse reactions; medical conditions that required systemic immunosuppression, except physiological dose of systemic corticosteroids; active tuberculosis or hepatitis B or C or HIV infection or patients receiving live attenuated vaccine within 30 days before or after the start of IMFINZI.

A combination of chemotherapy and radiation therapy (“radiochemotherapy”) is used, inter alia, in the treatment of tumors of the rectum, of the cervix, of the lungs, of the breasts, of the esophagus and in head and neck tumors.

Differential effects of NSC 631570 in modulating radiation toxicity of human cancer cell lines and its protective effect in normal human fibroblasts suggest that this agent may be beneficial for clinical radiochemotherapy (Cordes N., Plasswilm L., Bamber M., Rodemann H. P. Ukrain®, an alkaloid thiophosphoric acid derivate of Chelidonium majus L. protects human fibroblasts but not human tumor cells in vitro against ionizing radiation.

Patients after surgery and other significant treatments such as radio-chemotherapy and with ex- tensive functional deficits should receive rehabilitation according to their individual context factors (occupation, profession, home situation, hobby activities) (D).

Several strategies to intensify conventional chemotherapy have been evaluated in prospective studies, in some cases with promising results; they may be equally effective compared to chemoradiotherapy (34, e3).

After the application of radiochemotherapy, patients with the CC genotype showed significantly better survival than patients who carried a G allele (P=0.048).

FIG. 21 shows the survival curve of patients with laryngeal carcinoma who were given a combined radiochemotherapy.

For patients who were given radiochemotherapy, the age at the time of primary diagnosis proved to be the best prognostic factor (P=0.013), followed by the ?7235C>G polymorphism.

In the case that the cervical cancer has spread beyond the cervix, it must be decided on an individual case basis, whether surgery is possible, or, whether radio chemotherapy, chemotherapy, or radiation therapy is the best protective treatment for the patient and will maintain the patient's quality of life.

Important information for future clinical treatment improvements can also be gained from testing radiosensitizers (concurrent radiochemotherapy) and differentiation-inducing substances.

In the current study generation, further optimized application of myeloablative radiochemotherapy as well as combined immuno-chemotherapy should be achieved.

Another risk factor for the development of postoperative fistulas is preoperative or postoperative radiochemotherapy [23] .

In advanced tumours, multimodal treatment concepts can be used in conjunction with the Department of Radiation Oncology, such as pre-or postoperative radio chemotherapy.

The subsequent therapy in the form of combined radiochemotherapy (radiation and chemotherapy) is the current standard treatment, but it is associated with a risk of long-term toxicity to healthy brain tissue, causing the patient to lose cognitive abilities.

Another study is set to investigate the immunotherapy in patients with unresectable stage III NSCLC who have received standard radiochemotherapy therapy.

Besides the surgical therapy shall the conservative treatment of head-neck carcinoma be discussed regarding the indicators and limits of induction chemo therapy, concomitant radio chemo therapy and solitary radio therapy focusing on organ and function preservation.

With combined chemoradiotherapy, tumor control can be significantly improved and—in prospective studies—median survival times of 31 to 90 months have been achieved (30, 36 –40, e1).